EyePoint Pharmaceuticals sees increase in Q1 revenue: 3 details

Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.

Advertisement

Three details from the financial report:

1. EyePoint’s cash and cash equivalents totaled $43.4 million at the end of the third quarter.

2. Operating expenses for the third quarter increased to $16.7 million from $5.6 million the prior year.

3. The company reported a third-quarter net loss of $19.2 million, or $0.20 per share, compared to a net loss of $7 million, or $0.15 per share, for the prior-year quarter.

More articles on supply chain:
Arkansas ASC pioneers rare, $150K dental robot — 5 details
OrthoIllinois selects HSTpathways software for ASC management
Frost & Sullivan recognizes NextGen Healthcare’s RCM solutions — 3 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.